<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39460768</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1432-0991</ISSN><JournalIssue CitedMedium="Internet"><Volume>81</Volume><Issue>12</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>26</Day></PubDate></JournalIssue><Title>Current microbiology</Title><ISOAbbreviation>Curr Microbiol</ISOAbbreviation></Journal><ArticleTitle>Repositioning of Antibiotics in the Treatment of Viral Infections.</ArticleTitle><Pagination><StartPage>427</StartPage><MedlinePgn>427</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">427</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00284-024-03948-7</ELocationID><Abstract><AbstractText>Drug repurposing, also known as drug repositioning, is a currently tested approach by which new uses are being assigned for already tested drugs. In this case there are antibiotics that are used to combat bacterial infections. However, antibiotics are among the drugs that have been studied for possible antiviral activities. Therefore, the aim of this work is to carry out a review of the studies of antibiotics that could be repositioned for the treatment of viral infections. Among the main antibiotics that have demonstrated antiviral activity are macrolides and glycopeptides. In addition, several antibiotics from the group of tetracyclines, fluoroquinolones, cephalosporins and aminoglycosides have also been studied for their antiviral activity. These antibiotics have demonstrated antiviral activity against both RNA and DNA viruses, including the recent pandemic virus SARS-CoV-2. Some of these antibiotics were selected in addition to its antiviral activity for their immunomodulatory and anti-inflammatory properties. Of the antibiotics that present antiviral activity, in many cases the mechanisms of action are not exactly known. The use of these antibiotics to combat viral infections remains controversial and is not generally accepted, since clinical trials are required to prove its effectiveness. Therefore, there is currently no antibiotic approved as antiviral therapy. Hence is necessary to present the studies carried out on antibiotics that can be repositioned in the future as antiviral drugs.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bustos-Hamdan</LastName><ForeName>Anaíd</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0001-9906-0227</Identifier><AffiliationInfo><Affiliation>Departamento de Atención a la Salud, Universidad Autónoma Metropolitana-Xochimilco, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bracho-Gallardo</LastName><ForeName>Jair Isidoro</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Maestria en Biología de la Reproducción Animal, Universidad Autónoma Metropolitana-Iztapalapa, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamdan-Partida</LastName><ForeName>Aída</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5827-3576</Identifier><AffiliationInfo><Affiliation>Departamento de Atención a la Salud, Universidad Autónoma Metropolitana-Xochimilco, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bustos-Martínez</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9763-754X</Identifier><AffiliationInfo><Affiliation>Departamento de Atención a la Salud, Universidad Autónoma Metropolitana-Xochimilco, Mexico City, Mexico. jbustos@correo.xoc.uam.mx.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Microbiol</MedlineTA><NlmUniqueID>7808448</NlmUniqueID><ISSNLinking>0343-8651</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="Y">Drug Repositioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="Y">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014777" MajorTopicYN="Y">Virus Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>11</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460768</ArticleId><ArticleId IdType="pmc">PMC11512906</ArticleId><ArticleId IdType="doi">10.1007/s00284-024-03948-7</ArticleId><ArticleId IdType="pii">10.1007/s00284-024-03948-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cook MA, Wright GD (2022) The past, present, and future of antibiotics. Sci Transl Med 14(657):eabo7793. 10.1126/scitranslmed.abo7793</Citation><ArticleIdList><ArticleId IdType="pubmed">35947678</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker DE (2013) Antimicrobial drugs. Anesth Prog 60:111–122. 10.2344/0003-3006-60.3.111. (quiz 123)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3771199</ArticleId><ArticleId IdType="pubmed">24010989</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekerman E, Einav S (2015) Infectious disease. Combating emerging viral threats. Science 348:282–283. 10.1126/science.aaa3778</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4419706</ArticleId><ArticleId IdType="pubmed">25883340</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cui R, Li G, Gao Q, Yuan S, Altmeyer R, Zou G (2016) Teicoplanin inhibits Ebola pseudovirus infection in cell culture. Antivir Res 125:1–7. 10.1016/j.antiviral.2015.11.003</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7113690</ArticleId><ArticleId IdType="pubmed">26585243</ArticleId></ArticleIdList></Reference><Reference><Citation>Colson P, Raoult D (2016) Fighting viruses with antibiotics: an overlooked path. Int J Antimicrob Agents 48:349–352. 10.1016/j.ijantimicag.2016.07.004</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7134768</ArticleId><ArticleId IdType="pubmed">27546219</ArticleId></ArticleIdList></Reference><Reference><Citation>Flint SJ, Racaniello VR, Rall GF, Hatziioannou T, Skalka AM (2020) Principles of virology, 5th edn. ASM Press, Washington, DC</Citation></Reference><Reference><Citation>Domingo E (2016) Molecular basis of genetic variation of viruses: error-prone replication. In: Virus as populations. Academic Press, Cambridge, pp 35–71. 10.1016/B978-0-12-800837-9.00002-2</Citation></Reference><Reference><Citation>Baltimore D (1971) Expression of animal virus genomes. Bacteriol Rev 35:235–241. 10.1128/br.35.3.235-241.1971</Citation><ArticleIdList><ArticleId IdType="pmc">PMC378387</ArticleId><ArticleId IdType="pubmed">4329869</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalla D (2019) Using human experience to identify drug repurposing opportunities: theory and practice. Br J Clin Pharmacol 85:680–689. 10.1111/bcp.13851</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6422651</ArticleId><ArticleId IdType="pubmed">30648285</ArticleId></ArticleIdList></Reference><Reference><Citation>Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet 380:2095–2128. 10.1016/S0140-6736(12)61728-0</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10790329</ArticleId><ArticleId IdType="pubmed">23245604</ArticleId></ArticleIdList></Reference><Reference><Citation>Darby EM, Trampari E, Siasat P, Gaya MS, Alav I, Webber MA, Blair JMA (2023) Molecular mechanisms of antibiotic resistance revisited. Nat Rev Microbiol 21:280–295. 10.1038/s41579-022-00820-y</Citation><ArticleIdList><ArticleId IdType="pubmed">36411397</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W, Sanderson PE, Zheng W (2016) Drug combination therapy increases successful drug repositioning. Drug Discov Today 21:1189–1195. 10.1016/j.drudis.2016.05.015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4907866</ArticleId><ArticleId IdType="pubmed">27240777</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahal N, Nahata MC (1992) The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann Pharmacother 26:46–55. 10.1177/106002809202600112</Citation><ArticleIdList><ArticleId IdType="pubmed">1318761</ArticleId></ArticleIdList></Reference><Reference><Citation>Girard AE, Girard D, English AR, Gootz TD, Cimochowski CR, Faiella JA, Haskell SL, Retsema JA (1987) Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob Agents Chemother 3:1948–1954. 10.1128/AAC.31.12.1948</Citation><ArticleIdList><ArticleId IdType="pmc">PMC175833</ArticleId><ArticleId IdType="pubmed">2830841</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliver ME, Hinks TSC (2021) Azithromycin in viral infections. Rev Med Virol 31:1–13. 10.1002/rmv.2163</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7536932</ArticleId><ArticleId IdType="pubmed">32969125</ArticleId></ArticleIdList></Reference><Reference><Citation>Gielen V, Johnston SL, Edwards MR (2010) Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J 36:646–654. 10.1183/09031936.00095809</Citation><ArticleIdList><ArticleId IdType="pubmed">20150207</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoshnood S, Shirani M, Dalir A, Moradi M, Haddadi MH, Sadeghifard N, Birjandi FS, Yashmi I, Heidary M (2022) Antiviral effects of azithromycin: a narrative review. Biomed Pharmacother 147:112682. 10.1016/j.biopha.2022.112682</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8813546</ArticleId><ArticleId IdType="pubmed">35131658</ArticleId></ArticleIdList></Reference><Reference><Citation>Abadi B, Ilaghi M, Shahsavani Y, Faramarzpour M, Oghazian MB, Rahimi HR (2023) Antibiotics with antiviral and anti-inflammatory potential against Covid-19: a review. Curr Rev Clin Exp Pharmacol 18:51–63. 10.2174/2772432817666220106162013</Citation><ArticleIdList><ArticleId IdType="pubmed">34994339</ArticleId></ArticleIdList></Reference><Reference><Citation>Yacouba A, Olowo-Okere A, Yunusa I (2021) Repurposing of antibiotics for clinical management of COVID-19: a narrative review. Ann Clin Microbiol Antimicrob 20:37. 10.1186/s12941-021-00444-9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8139224</ArticleId><ArticleId IdType="pubmed">34020659</ArticleId></ArticleIdList></Reference><Reference><Citation>Asner S, Waters V, Solomon M, Yau Y, Richardson SE, Grasemann H, Gharabaghi F, Tran D (2012) Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis. J Cyst Fibros 11:433–439. 10.1016/j.jcf.2012.04.006</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7105203</ArticleId><ArticleId IdType="pubmed">22579414</ArticleId></ArticleIdList></Reference><Reference><Citation>Asada M, Yoshida M, Suzuki T, Hatachi Y, Sasaki T, Yasuda H, Nakayama K, Nishimura H, Nagatomi R, Kubo H, Yamaya M (2009) Macrolide antibiotics inhibit respiratory syncytial virus infection in human airway epithelial cells. Antivir Res 83:191–200. 10.1016/j.antiviral.2009.05.003</Citation><ArticleIdList><ArticleId IdType="pubmed">19463856</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigelman A, Isaacson-Schmid M, Sajol G (2015) Randomized trial to evaluate azithromycin’s effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol 135:1171–1178. 10.1016/j.jaci.2014.10.001</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4426225</ArticleId><ArticleId IdType="pubmed">25458910</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosquera RA, Gomez-Rubio AM, Harris T, Yadav A, McBeth K et al (2016) Anti-inflammatory effect of prophylactic macrolides on children with chronic lung disease: a protocol for a double-blinded randomised controlled trial. BMJ Open 6:e012060. 10.1136/bmjopen-2016-012060</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5030609</ArticleId><ArticleId IdType="pubmed">27638496</ArticleId></ArticleIdList></Reference><Reference><Citation>Du X, Zuo X, Meng F, Han C, Ouyang W, Han Y, Gu Y, Zhao X, Xu F, Qin FX (2021) Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2 viruses by azithromycin. Cell Prolif 54:e12953. 10.1111/cpr.12953</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7744835</ArticleId><ArticleId IdType="pubmed">33211371</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigelman A, Goss CW, Wang J, Srinivasan M, Boomer J et al (2024) Azithromycin therapy in infants hospitalized for respiratory syncytial virus bronchiolitis: airway matrix metalloproteinase-9 levels and subsequent recurrent wheeze. Ann Allergy Asthma Immunol 132(5):623–629. 10.1016/j.anai.2024.01.001</Citation><ArticleIdList><ArticleId IdType="pubmed">38237675</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee N, Wong CK, Chan MCW, Yeung ESL, Tam WWS et al (2018) Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: a randomized controlled trial. Antiviral Res 144:48–56. 10.1016/j.antiviral.2017.05.008</Citation><ArticleIdList><ArticleId IdType="pubmed">28535933</ArticleId></ArticleIdList></Reference><Reference><Citation>Retallack H, Di Lullo E, Arias C, Knopp KA, Laurie MT et al (2016) Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci USA 113:14408–14413. 10.1073/pnas.1618029113</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5167169</ArticleId><ArticleId IdType="pubmed">27911847</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Zu S, Deng YQ, Li D, Parvatiyar K et al (2019) Azithromycin protects against Zika virus infection by upregulating virus-induced type I and III interferon responses. J Antimicrob Agents Chemother 63(789–793):e00394-e419. 10.1128/AAC.00394-19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6879226</ArticleId><ArticleId IdType="pubmed">31527024</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosseboeuf E, Aubry M, Nhan T, de Pina JJ, Rolain JM, Raoult D, Musso D (2018) Azithromycin inhibits the replication of Zika virus. J Antivir Antiretrovir 10:6–11. 10.4172/1948-5964.1000173</Citation></Reference><Reference><Citation>Zeng L, Jiang X, Guo X (2019) Spiramycin and azithromycin, safe for administration to children, exert antiviral activity against enterovirus A71 in vitro and in vivo. Int J Antimicrob Agents 53:362–369. 10.1016/j.ijantimicag.2018.12.009</Citation><ArticleIdList><ArticleId IdType="pubmed">30599241</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L et al (2020) Hydroxychloroquine and azithromycin as a treatment of COVID19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 56:105949. 10.1016/j.ijantimicag.2020.105949</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102549</ArticleId><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohe M, Shida H, Jodo S, Kusunoki Y, Seki M, Furuya K, Goudarzi H (2020) Macrolide treatment for COVID-19: will this be the way forward? BioSci Trends 14:159–160. 10.5582/bst.2020.03058</Citation><ArticleIdList><ArticleId IdType="pubmed">32249257</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (2024) International registry clinical trials platform. https://www.who.int/clinical-trials-registry-platform/the-ictrp-search-portal. Accessed 13 Sept 2024</Citation></Reference><Reference><Citation>National Institutes of Health (2024). https://www.clinicaltrials.gov/. Accessed 13 Sept 2024</Citation></Reference><Reference><Citation>Brouqui P, Million M, Parola P, Mccullough PA, Raoult D (2023) Outcomes after early treatment with hydroxychloroquine and azithromycin: an analysis of a database of 30,423 COVID-19 patients. New Microbes New Infect 55:101188. 10.1016/j.nmni.2023.101188</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10651676</ArticleId><ArticleId IdType="pubmed">38024333</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamel AM, Monem MSA, Sharaf NA, Magdy N, Farid SF (2022) Efficacy and safety of azithromycin in Covid-19 patients: a systematic review and meta-analysis of randomized clinical trials. Rev Med Virol 32:e2258. 10.1002/rmv.2258</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8209938</ArticleId><ArticleId IdType="pubmed">34077600</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group (2021) Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet 397:605–612. 10.1016/S0140-6736(21)00149-5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7884931</ArticleId><ArticleId IdType="pubmed">33545096</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan H, Peto R, Henao-Restrepo AM et al (2021) Repurposed antiviral drugs for Covid-19—interim WHO Solidarity Trial Results. N Engl J Med 384:497–511. 10.1056/NEJMoa2023184</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7727327</ArticleId><ArticleId IdType="pubmed">33264556</ArticleId></ArticleIdList></Reference><Reference><Citation>Pani A, Lauriola M, Romandini A, Scaglione F (2020) Macrolides and viral infections: focus on azithromycin in COVID-19 pathology. Int J Antimicrob Agents 56:106053. 10.1016/j.ijantimicag.2020.106053</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7286256</ArticleId><ArticleId IdType="pubmed">32534189</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang YJ, Kwon HJ, Lee BJ (2006) Effect of clarithromycin on rhinovirus-16 infection in A549 cells. Eur Respir J 27:12–19. 10.1183/09031936.06.00008005</Citation><ArticleIdList><ArticleId IdType="pubmed">16387930</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujita K, Shimizu T, Majima Y, Sakakura Y (2000) Effects of macrolides on interleukin-8 secretion from human nasal epithelial cells. Eur Arch Otorhinolaryngol 257:199–204. 10.1007/s004050050222</Citation><ArticleIdList><ArticleId IdType="pubmed">10867834</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Kempen M, Bachert C, Van Cauwenberge P (1999) An update on the pathophysiology of rhinovirus upper respiratory tract infections. Rhinology 37:97–103</Citation><ArticleIdList><ArticleId IdType="pubmed">10567986</ArticleId></ArticleIdList></Reference><Reference><Citation>Arikata M, Itoh Y, Shichinohe S, Nakayama M, Ishigaki H, Kinoshita T, Le MQ, Kawaoka Y, Ogasawara K, Shimizu T (2019) Efficacy of clarithromycin against H5N1 and H7N9 avian influenza a virus infection in cynomolgus monkeys. Antivir Res 171:104–109. 10.1016/j.antiviral.2019.104591</Citation><ArticleIdList><ArticleId IdType="pubmed">31421167</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto K, Hosogaya N, Sakamoto N, Yoshida H, Ishii H, Yatera K, Izumikawa K, Yanagihara K, Mukae H (2021) Efficacy of clarithromycin in patients with mild COVID-19 pneumonia not receiving oxygen administration: protocol for an exploratory, multicentre, open-label, randomised controlled trial (CAME COVID-19 study). BMJ Open 11(9):e053325. 10.1136/bmjopen-2021-053325</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8458001</ArticleId><ArticleId IdType="pubmed">34548368</ArticleId></ArticleIdList></Reference><Reference><Citation>Millán-Oñate J, Millan W, Mendoza LA, Sánchez CG, Fernandez-Suarez H, Bonilla-Aldana DK, Rodríguez-Morales AJ (2020) Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin. Ann Clin Microbiol Antimicrob 19:16. 10.1186/s12941-020-00358-y</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7180682</ArticleId><ArticleId IdType="pubmed">32331519</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashad A, Nafady A, Hassan MH, Mansour H, Taya U et al (2021) Therapeutic efficacy of macrolides in management of patients with mild COVID-19. Sci Rep 11:16361. 10.1038/s41598-021-95900-z</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8357809</ArticleId><ArticleId IdType="pubmed">34381155</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi E, Indalao IL, Sawabuchi T, Mizuno K, Sakai S, Kimoto T, Kim H, Kido H (2018) Clarithromycin suppresses induction of monocyte chemoattractant protein-1 and matrix metalloproteinase-9 and improves pathological changes in the lungs and heart of mice infected with influenza A virus. Comp Immunol Microbiol Infect Dis 56:6–13. 10.1016/j.cimid.2017.11.002</Citation><ArticleIdList><ArticleId IdType="pubmed">29406285</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Xia S, Zou P, Lu L (2019) Erythromycin estolate inhibits Zika virus infection by blocking viral entry as a viral inactivator. Viruses 11:1064. 10.3390/v11111064</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6893414</ArticleId><ArticleId IdType="pubmed">31731598</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Chen Y, Shi H, Zou P (2022) Erythromycin estolate is a potent inhibitor against HCoV-OC43 by directly inactivating the virus particle. Front Cell Infect Microbiol 12:905248. 10.3389/fcimb.2022.905248</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9301004</ArticleId><ArticleId IdType="pubmed">35873167</ArticleId></ArticleIdList></Reference><Reference><Citation>Desmonts de Lamache D, Moges R, Siddiq A, Allain T, Feener TD, Muench GP, McKenna N, Yates RM, Buret AG (2019) Immuno-modulating properties of tulathromycin in porcine monocyte-derived macrophages infected with porcine reproductive and respiratory syndrome virus. PLoS ONE 23:14. 10.1371/journal.pone.0221560</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6707645</ArticleId><ArticleId IdType="pubmed">31442273</ArticleId></ArticleIdList></Reference><Reference><Citation>Pomorska-Mól M, Kwit K, Czyżewska-Dors E, Pejsak Z (2019) Tulathromycin enhances humoral but not cellular immune response in pigs vaccinated against swine influenza. J Vet Pharmacol Ther 42:318–323. 10.1111/jvp.12742</Citation><ArticleIdList><ArticleId IdType="pubmed">30585339</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidary F, Gharebaghi R (2020) Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot 73:593–602. 10.1038/s41429-020-0336-z</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7290143</ArticleId><ArticleId IdType="pubmed">32533071</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaidi AK, Dehgani-Mobaraki P (2022) The mechanisms of action of ivermectin against SARS-CoV-2—an extensive review. J Antibiot 75:60–71. 10.1038/s41429-021-00491-6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8688140</ArticleId><ArticleId IdType="pubmed">34931048</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, Tham TC (2021) Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. Am J Ther 28(4):e434–e460. 10.1097/MJT.0000000000001402</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8248252</ArticleId><ArticleId IdType="pubmed">34145166</ArticleId></ArticleIdList></Reference><Reference><Citation>Popp M, Stegemann M, Metzendorf M-I, Gould S, Kranke P, Meybohm P, Skoetz N, Weibel S (2021) Ivermectin for preventing and treating COVID-19. Cochrane Database Syst Rev. 10.1002/14651858.CD015017.pub2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8406455</ArticleId><ArticleId IdType="pubmed">34318930</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayward G, Yu LM, Little P, Gbinigie O, Shanyinde M et al (2015) Ivermectin for COVID-19 in adults in the community (PRINCIPLE): an open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes. J Infect 88:106130. 10.1016/j.jinf.2024.106130</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10981761</ArticleId><ArticleId IdType="pubmed">38431155</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahne D, Leimkuhler C, Lu W, Walsh C (2005) Glycopeptide and lipoglycopeptide antibiotics. Chem Rev 105:425–448. 10.1021/cr030103a</Citation><ArticleIdList><ArticleId IdType="pubmed">15700951</ArticleId></ArticleIdList></Reference><Reference><Citation>Acharya Y, Bhattacharyya S, Dhanda G, Haldar J (2022) Emerging roles of glycopeptide antibiotics: moving beyond gram-positive bacteria. ACS Infect Dis 8:1–28. 10.1021/acsinfecdis.1c00367</Citation><ArticleIdList><ArticleId IdType="pubmed">34878254</ArticleId></ArticleIdList></Reference><Reference><Citation>Balzarini J, Pannecouque C, De Clercq E, Pavlov AY, Printsevskaya SS, Miroshnikova OV, Reznikova MI, Preobrazhenskaya MN (2003) Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics. J Med Chem 46:2755–2764. 10.1021/jm0300882</Citation><ArticleIdList><ArticleId IdType="pubmed">12801238</ArticleId></ArticleIdList></Reference><Reference><Citation>Preobrazhenskaya MN, Olsufyeva EN (2006) Polycyclic peptide and glycopeptide antibiotics and their derivatives as inhibitors of HIV entry. Antivir Res 71:227–236. 10.1016/j.antiviral.2006.04.008</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7114112</ArticleId><ArticleId IdType="pubmed">16720053</ArticleId></ArticleIdList></Reference><Reference><Citation>Szűcs Z, Kelemen V, Le Thai S, Csávás M, Rőth E, Batta G, Stevaert A, Vanderlinden E, Naesens L, Herczegh P, Borbás A (2018) Structure activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents. Eur J Med Chem 1:1017–1030. 10.1016/j.ejmech.2018.08.058</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7115582</ArticleId><ArticleId IdType="pubmed">30170320</ArticleId></ArticleIdList></Reference><Reference><Citation>De Burghgraeve T, Kaptein SJ, Ayala-Nunez NV, Mondotte JA, Pastorino B, Printsevskaya SS, de Lamballerie X, Jacobs M, Preobrazhenskaya M, Gamarnik AV, Smit JM, Neyts J (2012) An analogue of the antibiotic teicoplanin prevents flavivirus entry in vitro. PLoS ONE 7:e37244. 10.1371/journal.pone.0037244</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3356272</ArticleId><ArticleId IdType="pubmed">22624001</ArticleId></ArticleIdList></Reference><Reference><Citation>Obeid S, Printsevskaya SS, Olsufyeva EN, Dallmeier K, Durantel D, Zoulim F, Preobrazhenskaya MN, Neyts J, Paeshuyse J (2011) Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibiotics. J Antimicrob Chem 66:1287–1294. 10.1093/jac/dkr104</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7109641</ArticleId><ArticleId IdType="pubmed">21436155</ArticleId></ArticleIdList></Reference><Reference><Citation>Maieron A, Kerschner H (2012) Teicoplanin therapy leading to a significant decrease in viral load in a patient with chronic hepatitis C. J Antimicrob Chemother 67:2537–2538. 10.1093/jac/dks217</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7109765</ArticleId><ArticleId IdType="pubmed">22687891</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou N, Pan T, Zhang J, Li Q, Zhang X, Bai C, Huang F, Peng T, Zhang J, Liu C, Tao L, Zhang H (2016) Glycopeptide antibiotics potently inhibit cathepsin l in the late endosome/lysosome and block the entry of ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J Biol Chem 291:9218–9232. 10.1074/jbc.M116.716100</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4861487</ArticleId><ArticleId IdType="pubmed">26953343</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu F, Pan T, Huang F, Ying R, Liu J, Fan H, Zhang J, Liu W, Lin Y, Yuan Y et al (2022) Glycopeptide antibiotic teicoplanin inhibits cell entry of SARS-CoV-2 by suppressing the proteolytic activity of cathepsin L. Front Microbiol 12:884034. 10.3389/fmicb.2022.884034</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9096618</ArticleId><ArticleId IdType="pubmed">35572668</ArticleId></ArticleIdList></Reference><Reference><Citation>Bereczki I, Vimberg V, Lőrincz E, Papp H, Nagy L et al (2022) Semisynthetic teicoplanin derivatives with dual antimicrobial activity against SARS-CoV-2 and multiresistant bacteria. Sci Rep 12:16001. 10.1038/s41598-022-20182-y</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9511441</ArticleId><ArticleId IdType="pubmed">36163239</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron SA, Devaux C, Colson P, Raoult D, Rolain JM (2020) Teicoplanin: analternative drug for the treatment of COVID-19? Int J Antimicrob Agents 55:105112. 10.1016/j.ijantimicag.2020.105944</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102624</ArticleId><ArticleId IdType="pubmed">32179150</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L, Li Y, Shi T, Zhu Z, Zhao J, Xie Y, Wen J, Guo S, Wang J, Ding J, Liang C, Shan G, Li Q, Ge M, Cen S (2023) Teicoplanin derivatives block spike protein mediated viral entry as pan-SARS-CoV-2 inhibitors. Biomed Pharmacother 158:114213. 10.1016/j.biopha.2023.114213</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9808420</ArticleId><ArticleId IdType="pubmed">36916436</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceccarelli G, Alessandri F, d’Ettorre G, Borrazzo C, Spagnolello O, Oliva A, Ruberto F, Mastroianni CM, Pugliese F, Venditti M, Intensive Care COVID-19 Study Group of Sapienza University (2020) Is teicoplanin a complementary treatment option for COVID-19? The question remains. Int J Antimicrob Agents 56:106–112. 10.1016/j.ijantimicag.2020.106029</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7245324</ArticleId><ArticleId IdType="pubmed">32454071</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasar Z, Yemisen M, Yasar H, Ertaş A, Meric K, Sahin S (2021) Can treatment with teicoplanin improve the prognosis of COVID-19 patients? Int J Clin Pract 75(11):e14752. 10.1111/ijcp.14752</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8646897</ArticleId><ArticleId IdType="pubmed">34431178</ArticleId></ArticleIdList></Reference><Reference><Citation>Printsevskaya SS, Solovieva SE, Olsufyeva EN, Mirchink EP, Isakova EB, De Clercq E, Balzarini J, Preobrazhenskaya MN (2018) Structure-activity relationship studies of a series of antiviral and antibacterial aglycon derivatives of the glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin. J Med Chem 48:3885–3890. 10.1021/jm0500774</Citation><ArticleIdList><ArticleId IdType="pubmed">15916441</ArticleId></ArticleIdList></Reference><Reference><Citation>Szűcs Z, Naesens L, Stevaert A, Ostorházi E, Batta G, Herczegh P, Borbás A (2020) Reprogramming of the antibacterial drug vancomycin results in potent antiviral agents devoid of antibacterial activity. Pharmaceuticals (Basel) 13:139. 10.3390/ph13070139</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7407158</ArticleId><ArticleId IdType="pubmed">32610683</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozza G, Fortuna M, Meggio F, Sarno S, Kubbutat MHG et al (2018) Hydrophobic derivatives of glycopeptide antibiotics as inhibitors of protein kinases. Biochemistry (Mosc) 83:1222–1230. 10.1134/S0006297918100073</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7088347</ArticleId><ArticleId IdType="pubmed">30472959</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinter G, Bereczki I, Batta G, Otvos R, Sztaricskai F et al (2010) Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity. Bioorg Med Chem Lett 20:2713–2717. 10.1016/j.bmcl.2010.03.080</Citation><ArticleIdList><ArticleId IdType="pubmed">20381348</ArticleId></ArticleIdList></Reference><Reference><Citation>Sipos A, Mate G, Roth E, Borbas A, Batta G (2012) Synthesis of fluorescent ristocetin aglycon derivatives with remarkable antibacterial and antiviral activities. Eur J Med Chem 58:361–367. 10.1016/j.ejmech.2012.10.030</Citation><ArticleIdList><ArticleId IdType="pubmed">23149298</ArticleId></ArticleIdList></Reference><Reference><Citation>Sipos A, Török Z, Rőth E, Kiss-Szikszai A, Batta G, Bereczki I, Fejes Z, Borbás A, Ostorházi E, Rozgonyi F, Naesens L, Herczegh P (2012) Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities. Bioorg Med Chem Lett 22:7092–7096. 10.1016/j.bmcl.2012.09.079</Citation><ArticleIdList><ArticleId IdType="pubmed">23099097</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopra I, Roberts M (2001) Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65:232–260. 10.1128/MMBR.65.2.232-260.2001</Citation><ArticleIdList><ArticleId IdType="pmc">PMC99026</ArticleId><ArticleId IdType="pubmed">11381101</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturtz FG (1998) Antimurine retroviral effect of doxycycline. Methods Find Exp Clin Pharmacol 20:643–647. 10.1358/mf.1998.20.8.487489</Citation><ArticleIdList><ArticleId IdType="pubmed">9922979</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothan HA, Mohamed Z, Paydar M, Rahman NA, Yusof R (2014) Inhibitory effect of doxycycline against dengue virus replication in vitro. Arch Virol 159:711–718. 10.1007/s00705-013-1880-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24142271</ArticleId></ArticleIdList></Reference><Reference><Citation>Fredeking TM, Zavala-Castro JE, González-Martínez P, Moguel-Rodríguez W, Sanchez EC, Foster MJ, Diaz-Quijano FA (2015) Dengue patients treated with doxycycline showed lower mortality associated to a reduction in IL-6 and TNF levels. Recent Pat Antiinfect Drug Discov 10:51–58. 10.2174/1574891x10666150410153839</Citation><ArticleIdList><ArticleId IdType="pubmed">25858261</ArticleId></ArticleIdList></Reference><Reference><Citation>Teoh TC, Al-Harbi SJ, Abdulrahman AY, Rothan HA (2021) Doxycycline interferes with zika virus serine protease and inhibits virus replication in human skin fibroblasts. Molecules 26:1–8. 10.3390/molecules26144321</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8306286</ArticleId><ArticleId IdType="pubmed">34299596</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu ZC, Wang X, Wei JC, Li BB, Shao DH, Li YM, Liu K, Shi YY, Zhou B, Qiu YF, Ma ZY (2015) Antiviral activity of doxycycline against vesicular stomatitis virus in vitro. FEMS Microbiol Lett 362:fnv195. 10.1093/femsle/fnv195</Citation><ArticleIdList><ArticleId IdType="pubmed">26459887</ArticleId></ArticleIdList></Reference><Reference><Citation>Bick MJ, Carroll JW, Gao G, Goff SP, Rice CM, MacDonald MR (2003) Expression of the zinc-finger antiviral protein inhibits alphavirus replication. J Virol 77:11555–11562. 10.1128/jvi.77.21.11555-11562.2003</Citation><ArticleIdList><ArticleId IdType="pmc">PMC229374</ArticleId><ArticleId IdType="pubmed">14557641</ArticleId></ArticleIdList></Reference><Reference><Citation>Sargiacomo C, Sotgia F, Lisanti MP (2020) COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? Aging 12:6511–6517. 10.18632/aging.103001</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7202514</ArticleId><ArticleId IdType="pubmed">32229706</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh TU, Parida S, Lingaraju MC, Kesavan M, Kumar D, Singh RK (2020) Drug repurposing approach to fight COVID-19. Pharmacol Rep 72:1479–1508. 10.1007/s43440-020-00155-6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7474498</ArticleId><ArticleId IdType="pubmed">32889701</ArticleId></ArticleIdList></Reference><Reference><Citation>De Clercq E (2006) Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert Rev Anti Infect Ther 4:291–302. 10.1586/14787210.4.2.291</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7105749</ArticleId><ArticleId IdType="pubmed">16597209</ArticleId></ArticleIdList></Reference><Reference><Citation>Stambouli N, Driss A, Gargouri F, Bahrini K, Arfaoui B et al (2022) COVID-19 prophylaxis with doxycycline and zinc in health care workers: a prospective, randomized, double-blind clinical trial. Int J Infect Dis 122:553–558. 10.1016/j.ijid.2022.06.016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212900</ArticleId><ArticleId IdType="pubmed">35724828</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmud R, Rahman MM, Alam I, Ahmed KGU, Kabir AKMH et al (2021) Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial. J Int Med Res 49:3000605211013550. 10.1177/03000605211013550</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8127799</ArticleId><ArticleId IdType="pubmed">33983065</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhar R, Kirkpatrick J, Gilbert L, Khanna A, Modi MM, Chawla RK, Dalal S, Maturu VN, Stern M, Keppler OT, Djukanovic R, Gadola SD (2023) Doxycycline for the prevention of progression of COVID-19 to severe disease requiring intensive care unit (ICU) admission: a randomized, controlled, open-label, parallel group trial (DOXPREVENT.ICU). PLoS ONE 18(1):e0280745. 10.1371/journal.pone.0280745</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9870104</ArticleId><ArticleId IdType="pubmed">36689456</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler CC, Yu LM, Dorward J, Gbinigie O, Hayward G (2021) Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet Respir Med 9:1010–1020. 10.1016/S2213-2600(21)00310-6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8315758</ArticleId><ArticleId IdType="pubmed">34329624</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra MK, Ghosh D, Duseja R, Basu A (2009) Antioxidant potential of minocycline in Japanese encephalitis virus infection in murine neuroblastoma cells: correlation with membrane fluidity and cell death. Neurochem Int 54:464–470. 10.1016/j.neuint.2009.01.022</Citation><ArticleIdList><ArticleId IdType="pubmed">19428790</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell JH, Burdo TH, Autissier P, Bombardier JP, Westmoreland SV, Soulas C, Williams KC (2011) Minocycline inhibition of monocyte activation correlates with neuronal protection in SIV NeuroAIDS. PLoS ONE 6:e18688. 10.1371/journal.pone.0018688</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3071838</ArticleId><ArticleId IdType="pubmed">21494695</ArticleId></ArticleIdList></Reference><Reference><Citation>Szeto GL, Brice AK, Yang HC, Barber SA, Siliciano RF, Clements JE (2010) Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+T cells. J Infect Dis. 10.1086/651277</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3739045</ArticleId><ArticleId IdType="pubmed">20205570</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaelis M, Kleinschmidt MC, Doerr HW, Cinatl J Jr (2007) Minocycline inhibits West Nile virus replication and apoptosis in human neuronal cells. J Antimicrob Chem 60:981–986. 10.1093/jac/dkm307</Citation><ArticleIdList><ArticleId IdType="pubmed">17872917</ArticleId></ArticleIdList></Reference><Reference><Citation>Leela SL, Srisawat C, Sreekanth GP, Noisakran S, Yenchitsomanus PT, Limjindaporn T (2016) Drug repurposing of minocycline against dengue virus infection. Biochem Biophys Res Commun 478:410–416. 10.1016/j.bbrc.2016.07.029</Citation><ArticleIdList><ArticleId IdType="pubmed">27396621</ArticleId></ArticleIdList></Reference><Reference><Citation>Josset L, Zeng H, Kelly SM, Tumpey TM, Katze MG (2014) Transcriptomic characterization of the novel avian-origin Influenza A (H7N9) virus: specific host response and responses intermediate between avian (H5N1 and H7N7) and human (H3N2) viruses and implications for treatment options. MBio 5:e01102-e1113. 10.1128/mbio.01102-13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3950506</ArticleId><ArticleId IdType="pubmed">24496798</ArticleId></ArticleIdList></Reference><Reference><Citation>Bawage SS, Tiwari PM, Pillai S, Dennis VA, Singh SR (2019) Antibiotic minocycline prevents respiratory syncytial virus infection. Viruses 11:739. 10.3390/v11080739</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6723987</ArticleId><ArticleId IdType="pubmed">31405261</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J (2020) Fast identification of possible drug treatment of Coronavirus Disease-19 (COVID-19) through computational drug repurposing study. J Chem Inf Model 60:3277–3286. 10.1021/acs.jcim.0c00179</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7197972</ArticleId><ArticleId IdType="pubmed">32315171</ArticleId></ArticleIdList></Reference><Reference><Citation>Ezelarab HAA, Abbas SH, Hassan HA, Abuo-Rahma GEDA (2018) Recentupdates of fluoroquinolones as antibacterial agents. Arch Pharm (Weinheim) 351:e1800141. 10.1002/ardp.201800141</Citation><ArticleIdList><ArticleId IdType="pubmed">30048015</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma BN, Li R, Bernhoff E, Gutteberg TJ, Rinaldo CH (2011) Fluoroquinolones inhibit human polyomavirus BK (BKV) replication in primary human kidney cells. Antivir Res 92:115–123. 10.1016/j.antiviral.2011.07.012</Citation><ArticleIdList><ArticleId IdType="pubmed">21798289</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsutsumi M, Takada A, Takase S, Sawada M (1996) Effects of combination therapy with interferon and ofloxacin on chronic type C hepatitis: a pilot study. J Gastroenterol Hepatol 11:1006–1011. 10.1111/j.1440-1746.1996.tb00022.x</Citation><ArticleIdList><ArticleId IdType="pubmed">8985817</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima H, Kaita KD, Hawkins K, Uhanova J, Minuk GY (2002) Use of fluoroquinolones in patients with chronic hepatitis C virus-induced liver failure. Antimicrob Agents Chemother 46:3280–3282. 10.1128/AAC.46.10.3280-3282.2002</Citation><ArticleIdList><ArticleId IdType="pmc">PMC128783</ArticleId><ArticleId IdType="pubmed">12234860</ArticleId></ArticleIdList></Reference><Reference><Citation>Arroyo D, Chandran S, Vagefi PA, Wojciechowski D (2014) Adjuvant ciprofloxacin for persistent BK polyomavirus infection in kidney transplant recipients. J Transpl 3:171–174. 10.1155/2014/107459</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4034659</ArticleId><ArticleId IdType="pubmed">25349720</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali SH, Chandraker A, DeCaprio JA (2007) Inhibition of Simian virus 40 large T antigen helicase activity by fluoroquinolones. Antivir Ther 12:1–6. 10.1177/135965350701200104</Citation><ArticleIdList><ArticleId IdType="pubmed">17503741</ArticleId></ArticleIdList></Reference><Reference><Citation>Enoki Y, Ishima Y, Tanaka R, Sato K, Kimachi K (2015) Pleiotropic effects of levofloxacin, fluoroquinolone antibiotics, against influenza virus-induced lung injury. PLoS ONE 10:e0130248. 10.1371/journal.pone.0130248</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4473075</ArticleId><ArticleId IdType="pubmed">26086073</ArticleId></ArticleIdList></Reference><Reference><Citation>Karampela I, Dalamaga M (2020) Could respiratory fluoroquinolones, levofloxacin and moxifloxacin, prove to be beneficial as an adjunct treatment in COVID-19? Arch Med Res 51:741–742. 10.1016/j.arcmed.2020.06.004</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7275144</ArticleId><ArticleId IdType="pubmed">32546446</ArticleId></ArticleIdList></Reference><Reference><Citation>Metlay JP, Waterer GW (2020) Treatment of community-acquired pneumonia during the coronavirus disease 2019 (COVID-19) pandemic. Ann Intern Med 173:304–305. 10.7326/M20-2189</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7236892</ArticleId><ArticleId IdType="pubmed">32379883</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansbury L, Lim B, Baskaran V, Lim WS (2020) Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect Dis 81:266–275. 10.1016/j.jinf.2020.05.046</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255350</ArticleId><ArticleId IdType="pubmed">32473235</ArticleId></ArticleIdList></Reference><Reference><Citation>Marciniec K, Beberok A, Pęcak P, Boryczka S, Wrześniok D (2020) Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: preliminary in silico analysis. Pharmacol Rep 72:1553–1561. 10.1007/s43440-020-00169-0</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7561236</ArticleId><ArticleId IdType="pubmed">33063271</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardoso-Ortiz J, Leyva-Ramos S, Baines KM, Gómez-Durán CFA et al (2023) Novel ciprofloxacin and norfloxacin-tetrazole hybrids as potential antibacterial and antiviral agents: targeting S. aureus topoisomerase and SARS-CoV-2-MPro. J Mol Struct 15(1274):134507. 10.1016/j.molstruc.2022.134507</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9640164</ArticleId><ArticleId IdType="pubmed">36406777</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalhoff A, Shalit I (2003) Immunomodulatory effects of quinolones. Lancet Infect Dis 3:359–371. 10.1016/s1473-3099(03)00658-3</Citation><ArticleIdList><ArticleId IdType="pubmed">12781508</ArticleId></ArticleIdList></Reference><Reference><Citation>Bojkova D, Zöller N, Tietgen M, Steinhorst K, Bechtel M et al (2023) Repurposing of the antibiotic nitroxoline for the treatment of mpox. J Med Virol 95(3):e28652. 10.1002/jmv.28652</Citation><ArticleIdList><ArticleId IdType="pubmed">36897017</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold HS, Moellering RC (1996) Antimicrobial-drug resistance. N Engl J Med 335:1445–1453. 10.1056/NEJM199611073351907</Citation><ArticleIdList><ArticleId IdType="pubmed">8875923</ArticleId></ArticleIdList></Reference><Reference><Citation>Krause KM, Serio AW, Kane TR, Connolly LE (2016) Aminoglycosides: an overview. Cold Spring Harb Perspect Med 6:256–264. 10.1101/cshperspect.a027029</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888811</ArticleId><ArticleId IdType="pubmed">27252397</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopinath S, Kim MV, Rakib T, Wong PW, van Zandt M, Barry NA, Kaisho T, Goodman AL, Iwasaki A (2018) Topical application of aminoglycoside antibiotics enhances host resistance to viral infections in a microbiota-independent manner. Nat Microbiol 3:611–621. 10.1038/s41564-018-0138-2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5918160</ArticleId><ArticleId IdType="pubmed">29632368</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder R, Waldsich C, Wank H (2000) Modulation of RNA function by aminoglycoside antibiotics. EMBO J 19:1–9. 10.1093/emboj/19.1.1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1171771</ArticleId><ArticleId IdType="pubmed">10619838</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalichem NSS, Bethapudi B, Mundkinajeddu D (2020) Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: plausible mechanism for repurposing strategy. Med Hypotheses 52:120–126. 10.1016/j.mehy.2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7286248</ArticleId><ArticleId IdType="pubmed">32554149</ArticleId></ArticleIdList></Reference><Reference><Citation>Khurshid Z, Zafar MS, Naseem M, Khan RS, Najeeb S (2018) Human oral defensins antimicrobial peptides: a future promising antimicrobial drug. Curr Pharm Des 24:1130–1137. 10.2174/1381612824666180403114615</Citation><ArticleIdList><ArticleId IdType="pubmed">29611481</ArticleId></ArticleIdList></Reference><Reference><Citation>Izquierdo-Dominguez A, Rojas-Lechuga MJ, Mullol J, Alobid I (2020) Olfactory dysfunction in the COVID-19 outbreak. J Invest Allergol Clin Immunol 30:317–326. 10.18176/jiaci.0567</Citation><ArticleIdList><ArticleId IdType="pubmed">32406374</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiem U, Heppner HJ, Pientka L (2011) Elderly patients with community-acquired pneumonia: optimal treatment strategies. Drugs Aging 28:519–537. 10.2165/11591980-000000000-00000</Citation><ArticleIdList><ArticleId IdType="pubmed">21721597</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Abduljabbar KA, Stone DU (2017) Risks of cefuroxime prophylaxis for postcataract endophthalmitis. Middle East Afr J Ophthalmol 24:24–29. 10.4103/meajo.MEAJO_255_16</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5433125</ArticleId><ArticleId IdType="pubmed">28546689</ArticleId></ArticleIdList></Reference><Reference><Citation>Durojaiye AB, Clarke JRD, Stamatiades GA, Wang C (2021) Repurposing cefuroxime for treatment of COVID-19: a scoping review of in silico studies. J Biomol Struct Dyn 39:4547–4554. 10.1080/07391102.2020.1777904</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7298880</ArticleId><ArticleId IdType="pubmed">32538276</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal MK, Ghosh S, Bhat HR, Naesens L, Singh UP (2020) Synthesis and biological evaluation of substituted phenyl azetidine-2-one sulphonyl derivatives as potential antimicrobial and antiviral agents. Bioorg Chem 104:104320. 10.1016/j.bioorg.2020.104320</Citation><ArticleIdList><ArticleId IdType="pubmed">33142428</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercorelli B, Palù G, Loregian A (2018) Drug repurposing for viral infectious diseases: how far are we? Trends Microbiol 26:865–876. 10.1016/j.tim.2018.04.004</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7126639</ArticleId><ArticleId IdType="pubmed">29759926</ArticleId></ArticleIdList></Reference><Reference><Citation>Varghese FS, Kaukinen P, Gläsker S, Bespalov M, Hanski L, Wennerberg K, Kümmerer BM, Ahola T (2016) Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses. Antivir Res 126:117–124. 10.1016/j.antiviral.2015.12.012</Citation><ArticleIdList><ArticleId IdType="pubmed">26752081</ArticleId></ArticleIdList></Reference><Reference><Citation>Jourdan JP, Bureau R, Rochais C, Dallemagne P (2020) Drug repositioning: a brief overview. J Pharm Pharmacol 72:1145–1151. 10.1111/jphp.13273</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262062</ArticleId><ArticleId IdType="pubmed">32301512</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>